Refractory Cytopenia with Multilineage Dysplasia
Associated Genetic Biomarkers
NCI Definition: A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines. (WHO, 2001) 
There are 3 clinical trials for refractory cytopenia with multilineage dysplasia, of which 3 are open and 0 are completed or closed. Of the trials that contain refractory cytopenia with multilineage dysplasia as an inclusion criterion, 2 are phase 2 (2 open) and 1 is phase 3 (1 open).
Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most common interventions in refractory cytopenia with multilineage dysplasia clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.